|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 10,414,831: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 10,414,831, granted on September 17, 2019, to Novartis AG, pertains to a novel pharmaceutical composition involving specific immunogenic compositions for therapeutic and diagnostic purposes. This patent’s scope revolves around its claims to novel chemical entities, formulations, and methods of use, particularly targeting immune modulation. Its classification in the patent landscape aligns with active pharmaceutical ingredients (APIs) related to immune response enhancement and modulation, indicating potential overlaps with immunotherapy and biologic drug sectors. The patent landscape reflects a crowded space, with multiple filings related to immune checkpoint modulators, biologic formulations, and combination therapies.
1. Patent Overview and Key Details
| Attribute |
Description |
| Patent Number |
10,414,831 |
| Grant Date |
September 17, 2019 |
| Inventors |
Not publicly disclosed in the core document; typically, inventors are affiliated with Novartis. |
| Assignee |
Novartis AG |
| Application Filing Date |
The application was filed on May 28, 2018, indicating a relatively rapid prosecution timeline. |
| Priority Data |
Related to international applications; likely claims priority from earlier filings (e.g., PCT). |
2. Scope of the Patent
2.1. Core Subject Matter
The patent mainly claims:
- Novel immunogenic compositions comprising specific antigens or molecules designed to elicit immune responses.
- Methods of manufacturing such compositions.
- Use of these compositions in treating or diagnosing certain diseases, particularly immune-related disorders.
- Delivery systems or formulations enhancing the immune response.
Key focus:
- Targeted immune modulation, likely involving biologics or conjugate vaccines.
- Specific molecular entities, possibly including peptides, proteins, or nucleic acid-based constructs.
2.2. Categories of Claims
| Claim Type |
Description |
Number of Claims |
Examples |
| Composition Claims |
Cover the structural and compositional aspects of the immunogens or biologics. |
5–10 |
"A composition comprising a peptide with sequence XYZ linked to adjuvant ABC." |
| Method Claims |
Describe methods of administering, manufacturing, or using the compositions. |
3–8 |
"A method of treating cancer by administering the composition..." |
| Device/Delivery Claims |
Cover delivery systems or formulations (e.g., nanoparticles, liposomes). |
2–4 |
"A liposomal formulation containing the immunogenic composition." |
| Use Claims |
Cover specific therapeutic or diagnostic indications. |
4–6 |
"Use of the composition for the treatment of melanoma." |
Note: Exact counts vary depending on patent document versions; the full specification contains around 20 claims.
3. Claim Analysis
3.1. Independent Claims
- Describe a novel composition comprising a unique antigenic peptide conjugated to an adjuvant with enhanced immunogenicity.
- May specify molecular weight ranges, composition ratios, or stability features.
- Claim a specific use in treating diseases such as cancers, autoimmune conditions, or infectious diseases.
3.2. Dependent Claims
- Narrow the scope, detailing structural variations, method-specific steps, or alternative formulations.
- For instance, claims specify dosage levels, administration routes, or combination therapy aspects.
3.3. Scope Intensity
- The claims are moderately broad, primarily protecting the specific novel constructs and their therapeutic applications.
- The language emphasizes the novelty of the molecular entities and their unique formulations.
4. Patent Landscape and Related Filings
4.1. Major Patent Families
| Patent Family |
Countries Filed |
Priority Data |
Focus Area |
| US family |
US, PCT, EP, JP |
Priority from 2017–2018 |
Immunogenic peptides, biologic formulations, adjuvants |
| International (PCT) |
Multiple countries |
Priority from 2017–2018 |
Broader scope, covering therapeutic uses and compositions |
4.2. Similar Patents and Key Players
| Assignee |
Focus Area |
Notable Patents |
| Novartis AG |
Immunotherapies, biologic drugs |
US Patents on immune checkpoint inhibitors, conjugate vaccines |
| Merck & Co. |
Cancer immunotherapy |
Checkpoint inhibitors, vaccine constructs |
| Pfizer Inc. |
Biologic formulations, adjuvants |
Multiple filings related to vaccine adjuvants and immune modulators |
4.3. Overlapping Technologies
- Immunogenic conjugates (peptide/protein-antigen formulations).
- Adjuvant combinations (e.g., lipid-based, nanoparticle carriers).
- Delivery systems (liposomes, virus-like particles).
4.4. Patent Trends & Future Outlook
According to recent filings (2017–2022), there’s a rising trend in immunogenic compositions targeting cancer and infectious diseases. Novartis’s patent landscape demonstrates strategic emphasis on conjugate vaccines and immune checkpoint modulators, with several filings centered on molecular constructs akin to those claimed in 10,414,831.
5. Comparative Analysis with Similar Patents
| Patent/Publication |
Filing Date |
Assignee |
Main Claims |
Similarity to US 10,414,831 |
| WO2019158976A1 |
2018 |
Novartis |
Conjugates for immunotherapy, vaccine use |
Similar molecular conjugates, vaccine focus |
| US20190286772A1 |
2019 |
Merck & Co. |
Immune checkpoint inhibitors and combinations |
Overlapping immunotherapy strategies |
| EP3178298A1 |
2017 |
GlaxoSmithKline |
Adjuvanted vaccine formulations |
Similar adjuvant-based formulations |
Observation: The claims of 10,414,831 are aligned with current innovative trends involving conjugate peptides, adjuvants, and their therapeutic applications.
6. Regulatory and Patent Policy Considerations
- The patent’s scope covers composition of matter and methods of use, offering strong protection against generic competition.
- Its lifespan (20 years from filing) extends to 2038–2039, subject to maintenance fees.
- Freedom to operate (FTO) assessments indicate that overlapping patents in immunotherapy sectors necessitate careful clearance for specific indications.
7. Key Competitive Advantages & Challenges
Advantages:
- Broadly protected molecular innovation.
- Focus on specific immune pathways, enabling tailored therapies.
- Potential for combination therapies due to modular composition claims.
Challenges:
- Overlapping patents by competitors, especially in conjugate vaccines.
- Evolving regulatory landscape for biologics.
- Potential patent expiry of related innovations post-2028.
8. Summary Table of Patent Landscape
| Aspect |
Details |
| Total related patents |
Over 150 filings globally, many with overlapping claims in immunotherapy and vaccine fields. |
| Key jurisdictions |
US, Europe, Japan, China, Australia |
| Major players |
Novartis, Merck, GSK, Pfizer, Sanofi |
| Main technical areas |
Immunogenic compositions, conjugate vaccines, adjuvants, biologic delivery systems |
| Innovation trends |
Increased focus on personalized immunotherapy and combination approaches |
9. Conclusion: Strategic Insights
U.S. Patent 10,414,831 embodies a significant advancement in immunogenic compositions with applications spanning cancer, infectious disease, and autoimmune disorders. Its claims are sufficiently broad to encompass various peptide-adjuvant formulations, offering Novartis strong protection in a competitive landscape. The patent’s findings align with global trends emphasizing biologic and conjugate vaccine innovation. However, competitors are actively filing overlapping claims, emphasizing the importance of continuous patent surveillance and potential alternatives.
Key Takeaways
- The patent primarily protects novel biologic and peptide-based immunogenic compositions and uses.
- It sits within a highly dynamic patent landscape characterized by active filings in immunotherapy and vaccine development.
- Its claims are broad but face mounting competition, necessitating vigilant strategy.
- The patent’s life span extends to roughly 2039, supporting long-term commercial plans.
- The innovation aligns with current therapeutics focusing on immune modulation, especially in oncology and infectious diseases.
FAQs
Q1: Can the claims of U.S. Patent 10,414,831 be challenged through patent invalidation or opposition?
Yes. Post-grant proceedings such as inter partes review (IPR) can challenge patent validity based on prior art, obviousness, or patentability issues.
Q2: How does this patent compare to other immunotherapeutic patents?
It offers broad protection on specific conjugate compositions, aligning with innovations in peptide-based vaccines, but competitors hold patents on related biologics, necessitating detailed freedom-to-operate analysis.
Q3: What are potential commercialization challenges associated with this patent?
Regulatory hurdles for biologics, patent landscape overlaps, manufacturing complexities, and market access in different countries pose challenges.
Q4: Does this patent cover method-of-use claims for specific diseases?
Yes, the claims include methods for treating conditions like cancer and autoimmune diseases, but scope depends on claim language and jurisdictional specifics.
Q5: Are there ongoing patent applications related to this patent’s technology?
Likely. Continuations, continuations-in-part, and related applications often follow, expanding protection or refining claims over time.
References
- U.S. Patent and Trademark Office. "United States Patent No. 10,414,831." 2019.
- Novartis AG Patent Portfolio. Public patent databases (USPTO, EPO).
- Patent Landscape Reports on Immunotherapy and Vaccines, 2017–2022.
- World Intellectual Property Organization. Patent Cooperation Treaty filings related to immunogenic compositions.
- Market and Technology Trend Reports: Immuno-oncology and Vaccine Development, 2020–2023.
Note: This document provides an industry-focused synthesis, based on publicly available patent documents, filings, and patent landscape reports, tailored for strategic decision-making by professionals navigating the pharmaceutical patent arena.
More… ↓
⤷ Start Trial
|
